Autonomize AI offers an Agentic AI Orchestration platform with pre-trained, ready-to-deploy AI agents that coordinate as intelligent copilots across regulated healthcare workflows. The platform is healthcare-native, emphasizing explainability, human-in-the-loop workflows, and enterprise-wide orchestration rather than generic generative AI. Its agents address use cases such as care management, utilization management, benefits checks, and chart reviews, and are reported to deliver measurable operational impact at scale. Reported operating metrics include 36,000 clinical hours saved per month, 100,000+ automated care plans created monthly, and up to 50% faster decisions for prior authorizations and claims. Customers include Top 20 Pharmaceuticals, Fortune 100 healthcare enterprises, and life sciences companies. The company says it will use new funding to scale the platform and further rewire healthcare operations to reduce clinician burden and improve patient outcomes. Autonomize AI provides a secure, cloud-based AI platform optimized for healthcare and life sciences that ingests multi-modal and unstructured medical data using pre-trained medical LLMs. Its product suite includes Autonomize Pixel for clinical-trial workflows and patient matching, Autonomize Wizard for multi-modal chart insights, and generative-AI capabilities for conversational search and summarization of internal data. The platform supports fine-tuning on private data, deployment into virtual private clouds, and a privacy filter that anonymizes PII and PHI. Launched in 2022 and headquartered in Austin, Texas, the company emphasizes human-centered workflows to augment knowledge workers and improve operational efficiency. Customers report rapid ROI and efficiency gains—SubjectWell said medical-records review became ten times more efficient and accurate. Autonomize AI plans to use new funding to boost R&D and commercialization to drive down costs and accelerate adoption across healthcare organizations.

Total raised

$32M

Funding rounds

2

Latest round

Series A

Latest activity

Jun 2025